The current gene therapy, which is being done at research hospitals, appears to be less effective than PCYC's Ibrutinib, whose drug treats CLL: Current gene therapy had the best percentage results for acute lymphocytic leukemia, or ALL. Compared to PCYC's 71% results gene therapy appears to be somewhat less effective for CLL, as follows:
"Penn doctors have treated the most cases so far [with gene therapy] — 59. Of the first 14 patients with CLL, four had complete remissions, four had partial ones and the rest did not respond.... Another 18 CLL patients were treated and half have responded so far." The total cost for gene therapy -- without any profit margin -- is $25k.
. . . the pressure might be a bit premature . . . because of the unknowns, gene therapy is likely to be used exclusively as a salvage treatment, available only to the sickest who have tried everything else . . . that said, gene therapy is clearly a rapidly developing technology that could ultimately obsolete a lot of drugs . . .